Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald L Andriole

Showing results (11-20 of 265) with videos related to

Pageof 27
Sort By:
Urology|January 28, 2015
Editorial commentBrandon Manley, Gerald L Andriole
European Urology|June 20, 2003
Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasiaGerald L Andriole, Roger Kirby
European Urology|December 5, 2012
Bad habits may be hard to breakGoutham Vemana, Gerald L Andriole
The Journal of Urology|January 18, 2011
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancerAlex Shteynshlyuger, Gerald L Andriole
Urology|September 24, 2013
Editorial commentGoutham Vemana, Gerald L Andriole
The Urologic Clinics of North America|February 16, 2010
Prostate cancer: to screen or not to screen?Alex Shteynshlyuger, Gerald L Andriole
European Urology|July 10, 2012
Active surveillance for prostate cancer: barriers to widespread adoptionGurdarshan S Sandhu, Gerald L Andriole
Expert Opinion on Emerging Drugs|March 1, 2006
Emerging drug therapies for benign prostatic hyperplasiaTravis L Bullock, Gerald L Andriole
Nature Clinical Practice. Urology|June 10, 2006
Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy?Robert L Grubb, Gerald L Andriole
Cancer|October 21, 2010
Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50"Gerald L Andriole, Adam S Kibel
Pageof 27

Showing results (11-20 of 265) with videos related to

Sort By:
Pageof 27
Urology|January 28, 2015
Editorial commentBrandon Manley, Gerald L Andriole
European Urology|June 20, 2003
Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasiaGerald L Andriole, Roger Kirby
European Urology|December 5, 2012
Bad habits may be hard to breakGoutham Vemana, Gerald L Andriole
The Journal of Urology|January 18, 2011
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancerAlex Shteynshlyuger, Gerald L Andriole
Urology|September 24, 2013
Editorial commentGoutham Vemana, Gerald L Andriole
The Urologic Clinics of North America|February 16, 2010
Prostate cancer: to screen or not to screen?Alex Shteynshlyuger, Gerald L Andriole
European Urology|July 10, 2012
Active surveillance for prostate cancer: barriers to widespread adoptionGurdarshan S Sandhu, Gerald L Andriole
Expert Opinion on Emerging Drugs|March 1, 2006
Emerging drug therapies for benign prostatic hyperplasiaTravis L Bullock, Gerald L Andriole
Nature Clinical Practice. Urology|June 10, 2006
Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy?Robert L Grubb, Gerald L Andriole
Cancer|October 21, 2010
Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50"Gerald L Andriole, Adam S Kibel
Pageof 27